» Articles » PMID: 29610203

Pyocyanin Inhibits Chlamydia Infection by Disabling Infectivity of the Elementary Body and Disrupting Intracellular Growth

Overview
Specialty Pharmacology
Date 2018 Apr 4
PMID 29610203
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The obligate intracellular bacterium is a widespread human pathogen that causes serious problems, including (but not limited to) infertility and blindness. Our search for novel antichlamydial metabolites from marine-derived microorganisms led to the isolation of pyocyanin, a small compound from Pyocyanin is an effective antichlamydial for all three spp. tested. It has a 50% inhibitory concentration (IC) of 0.019 to 0.028 μM, which is comparable to the IC of tetracycline. At concentrations as low as 0.0039 μM, pyocyanin disables infectivity of the chlamydial elementary body (EB). At 0.5 μM or higher concentrations, the continuous presence of pyocyanin also inhibits chlamydial growth in the inclusion during later stages of the developmental cycle. Oxidative stress, a major known antimicrobial mechanism of pyocyanin, appears to be responsible only for the inhibition of bacterial growth and not for the disinfection of EBs. Pyocyanin is well-tolerated by probiotic vaginal spp. Our findings suggest that pyocyanin is of therapeutic value for chlamydial infections and can serve as a valuable chemical probe for studying chlamydial biology.

Citing Articles

The two faces of pyocyanin - why and how to steer its production?.

Jablonska J, Augustyniak A, Dubrowska K, Rakoczy R World J Microbiol Biotechnol. 2023; 39(4):103.

PMID: 36864230 PMC: 9981528. DOI: 10.1007/s11274-023-03548-w.


Rhein inhibits infection by regulating pathogen-host cell.

Yu X, Xu Q, Chen W, Mai Z, Mo L, Su X Front Public Health. 2022; 10:1002029.

PMID: 36238249 PMC: 9552556. DOI: 10.3389/fpubh.2022.1002029.


Bortezomib Eliminates Persistent Infection through Rapid and Specific Host Cell Apoptosis.

Itoh R, Kurihara Y, Yoshimura M, Hiromatsu K Int J Mol Sci. 2022; 23(13).

PMID: 35806436 PMC: 9267172. DOI: 10.3390/ijms23137434.


Recent Antimicrobial Responses of Halophilic Microbes in Clinical Pathogens.

Santhaseelan H, Dinakaran V, Dahms H, Munir Ahamed J, Murugaiah S, Krishnan M Microorganisms. 2022; 10(2).

PMID: 35208871 PMC: 8874722. DOI: 10.3390/microorganisms10020417.


Inhibition of the futalosine pathway for menaquinone biosynthesis suppresses Chlamydia trachomatis infection.

Dudiak B, Nguyen T, Needham D, Outlaw T, McCafferty D FEBS Lett. 2021; 595(24):2995-3005.

PMID: 34741525 PMC: 9980418. DOI: 10.1002/1873-3468.14223.


References
1.
Fadel S, Eley A . Is lipopolysaccharide a factor in infectivity of Chlamydia trachomatis?. J Med Microbiol. 2008; 57(Pt 3):261-266. DOI: 10.1099/jmm.0.47237-0. View

2.
Reszka K, OMalley Y, McCormick M, Denning G, Britigan B . Oxidation of pyocyanin, a cytotoxic product from Pseudomonas aeruginosa, by microperoxidase 11 and hydrogen peroxide. Free Radic Biol Med. 2004; 36(11):1448-59. DOI: 10.1016/j.freeradbiomed.2004.03.011. View

3.
Hybiske K, Stephens R . Mechanisms of Chlamydia trachomatis entry into nonphagocytic cells. Infect Immun. 2007; 75(8):3925-34. PMC: 1952008. DOI: 10.1128/IAI.00106-07. View

4.
Abdelmohsen U, Cheng C, Reimer A, Kozjak-Pavlovic V, Ibrahim A, Rudel T . Antichlamydial sterol from the Red Sea sponge Callyspongia aff. implexa. Planta Med. 2015; 81(5):382-7. DOI: 10.1055/s-0035-1545721. View

5.
Igietseme J, Eko F, Black C . Chlamydia vaccines: recent developments and the role of adjuvants in future formulations. Expert Rev Vaccines. 2011; 10(11):1585-96. DOI: 10.1586/erv.11.139. View